ORI Logo ORI Logo Promoting Integrity in Research
Individual | Institutional
 
Home About ORI Privacy FOIA Sitemap Contact ORI
. Search ORI
.
.
.
. Sections
.
.
.Assurance
.Conferences
.Handling Misconduct
.International
.Policies / Regulations
.Publications
.RCR Education
.Research
.RIOs

.
. Newsletter
.
.
Latest Newsletter (PDF)
June 2008


Past Issues...

.
.
. Annual Report
.
.
ORI Annual Report 2007
PDF format

Annual Report
Past Reports...

.
. Graduate RCR
.
.
Graduate Education for RCR
Annual Report
New CGS publication identifies best practices in RCR
.

 
 

 
.

International - Misconduct Cases

. International Menu
.
.
.Introduction
.Websites
.Activity
.Misconduct Cases

.
.

Danes Deplore Publication Practice

Volume 8, No. 2, March 2000

An American communications company was found to have encouraged a dishonest act by the Danish Committee on Scientific Dishonesty (DCSD) for offering the authorship of a finished manuscript to a Danish researcher who did not participate in preparing the manuscript.

The DCSD came to that conclusion for the following reasons:

"The company wanted to convey the false impression that the review article which recommends the product of a particular company had been written by an independent and impartial expert, whereas it had in fact been written by authors associated with the company.

The company encouraged a violation of international regulations of authorship which state that authorship may only be claimed if considerable and independent efforts have been expended in the preparation of the article."
In its response to the DCSD, the American company asserted it had not committed a dishonest act because the content of the review article was true and the researcher could make corrections to the article, which contained no original data.

The DCSD commended the researcher for submitting the case and concluded that "it would be very deplorable, if the practise were to spread where experts lend their authority to articles which have been written by other persons at the instigation of the pharmaceutical manufacturer which persons cannot be considered above rendering a biased presentation. The medical profession should not be tempted by comfortable authorships to participate in such misleading conduct. . ."



 
.
This page last was updated on January 13, 2005
.
Legal Disclaimer / Accessibility

Adobe Reader icon
U.S. Department of Health and Human Services
Office of Research Integrity • 1101 Wootton Parkway • Suite 750 • Rockville, MD 20852
  Directions to ORI Office
Questions/suggestions about this web page? Contact ORI
. .